Your partner to unlock access to European patients
With over 30 years of experience, 240,000 patients treated annually across 60 therapy areas and $2.7b medicines delivered a year through our 4,000+ healthcare partners, Sciensus delivers a pan-European hub services model – purpose-built to navigate the complexity of launching and scaling specialty therapies across the region.
We’re the right partner to help increase the value of your relationships with manufacturers through expansion into new geographies, extension of capabilities and enhancement of your service offering.
Meet the Sciensus team at PCMG 2025
Clinical support services enhance your development journey from trials to commercialisation
Sciensus helps accelerate the launch and commercialisation of medicines across Europe, bringing products into the market and directly to patients to improve outcomes.
As a pan-European hub services organisation, we support services across the development journey. From early access programmes (EAP) to non-interventional studies and decentralised trial support. From compounding, distribution and product delivery to complex treatments at home and data collection of real-world evidence and patient reported outcomes. Our digital capabilities help us deliver higher patient adoption and retention across all therapeutic areas.
Why partners choose Sciensus
With 30+ years of in-market expertise, Sciensus has superior access to patients – our distribution and clinical care infrastructure enables us to help you get the right drug to the right patients faster and then we can provide the personalised support to drive adherence, reduce drop-off and collect real world data.
0 +
patient interactions across Europe
0
patients treated annually
0 +
relationships with hospitals, clinics and pharmacies
0 +
regimens supported across 125 different medicines
What we deliver for life sciences partners
Early access programmes
Including compassionate use, named patient programme and cohort approaches.
Real-world data
Digital engagement and real-time data capture, including adherence, symptoms, PROs – prospective and retrospective.
PASS studies
Non-interventional trial design and delivery across Phase II-IV, RWE, PASS/PAES and LCM.
Decentralised trials
Services to support decentralised trials, including in-home and remote clinical care (GCP-trained nurses, virtual support, safety monitoring), trial file management and direct-to-patient drug shipments.
Clinical supply chain
End-to-end distribution capability, where needed, including warehousing & delivery with stringent chain-of-control documentation.
We support patients across Europe to accelerate access to medicines. As such, we are perfectly positioned to generate new evidence and insights to support early access, launch and early commercialisation.
Noolie Gregory – Head of Evidence Generation
As a strategic partner, they have exceeded our expectations by finding global patients, who need our drugs, and enabling them to receive their life-extending medications.
Chief Commercial Officer at leading US Biotech company
Looking for a partner to support your model in Europe?
Explore how we can support your work across Europe – from early access to real-world outcomes.